Multiple effects of IL-21 on human NK cells in ex vivo expansion

Immunobiology

Volumn 220, Issue 7, 2015, Pages 876-888

  Li, Qi ^a   Ye, Lin Jie ^a   Ren, Hai Long ^a   Huyan, Ting ^a   Li, Jing ^a   Shi, Jun Ling ^a   Huang, Qing Sheng ^a  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Ex vivo expansion; IL 21; Natural killer (NK) cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 21; MESSENGER RNA; GRANZYME; INTERLEUKIN DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL DIVISION; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; GENE EXPRESSION; GRANZYME B GENE; HUMAN; HUMAN CELL; IFN GAMMA GENE; LIFESPAN; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; K562 CELL LINE; LEUKOCYTE COUNT; S PHASE CELL CYCLE CHECKPOINT;

APOPTOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84929503653     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.01.009     Document Type: Article

References (29)

1. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 2001, 167:1.
2. Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., Christensson B., Guven H., Bjorkstrom N.K., Soderdahl G., Cederlund K., Kimby E., Aschan J., Ringden O., Ljunggren H.G., Dilber M.S. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753.
3. Buddingh E.P., Schilham M.W., Ruslan S.E., Berghuis D., Szuhai K., Suurmond J., Taminiau A.H., Gelderblom H., Egeler R.M., Serra M., Hogendoorn P.C., Lankester A.C. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol. Immunother. 2011, 60:575.
4. Chen Y., Wang Y., Zhuang Y., Zhou F., Huang L. Mifepristone increases the cytotoxicity of uterine natural killer cells by acting as a glucocorticoid antagonist via ERK activation. PLoS ONE 2012, 7:e36413.
5. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res. 2010, 16:3901.
6. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22:633.
7. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., Singh H., Hurton L., Maiti S.N., Huls M.H., Champlin R.E., Cooper L.J., Lee D.A. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012, 7:e30264.
8. Dong H., Zhang Y., Xi H. The effects of epidural anaesthesia and analgesia on natural killer cell cytotoxicity and cytokine response in patients with epithelial ovarian cancer undergoing radical resection. J. Int. Med. Res. 2012, 40:1822.
9. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., Jonson A.L., Panoskaltsis-Mortari A., Curtsinger J., McKenna D., Dusenbery K., Bliss R., Downs L.S., Miller J.S. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98.
10. Habib T., Nelson A., Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J. Allergy Clin. Immunol. 2003, 112:1033.
11. Huang Q.S., Li Q., Huang Y., Shang P., Zhang M.J. Expansion of human natural killer cells ex vivo. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008, 24:1167.
12. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., Rigatos G., Papamichail M., Perez S.A. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother. 2010, 59:1781.
13. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376.
14. Jiang B., Wu X., Li X.N., Yang X., Zhou Y., Yan H., Wei A.H., Yan W. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21. Cell Immunol. 2014, 290:10.
15. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., Johnson K.A., Witek J.S., Senices M., Konz R.F., Wurster A.L., Donaldson D.D., Collins M., Young D.A., Grusby M.J. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559.
16. Li Q., Mei Q., Huyan T., Xie L., Che S., Yang H., Zhang M., Huang Q. Effects of simulated microgravity on primary human NK cells. Astrobiology 2013, 13:703.
17. Lim D.P., Jang Y.Y., Kim S., Koh S.S., Lee J.J., Kim J.S., Thi Phan M.T., Shin D.J., Shin M.G., Lee S.H., Yoon M., Kim S.K., Yoon J.H., Park M.H., Cho D. Effect of exposure to interleukin-21 at various time points on human natural killer cell culture. Cytotherapy 2014.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402.
19. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., Orchard P.J., Blazar B.R., Wagner J.E., Slungaard A., Weisdorf D.J., Okazaki I.J., McGlave P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051.
20. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57.
21. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 2006, 177:120.
22. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., Pui C.H., Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 2010, 28:955.
23. Santegoets S.J., Turksma A.W., Powell D.J., Hooijberg E., de Gruijl T.D. IL-21 in cancer immunotherapy: at the right place at the right time. Oncoimmunology 2013, 2:e24522.
24. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575.
25. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989, 47:187.
26. Vosshenrich C.A., Di Santo J.P. Cytokines: IL-21 joins the gamma(c)-dependent network?. Curr. Biol. 2001, 11:R175.
27. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., Kim G., Leonard W.J., Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003, 63:9016.
28. Wendt K., Wilk E., Buyny S., Schmidt R.E., Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007, 122:486.
29. Zamai L., Del Zotto G., Buccella F., Galeotti L., Canonico B., Luchetti F., Papa S. Cytotoxic functions and susceptibility to apoptosis of human CD56(bright) NK cells differentiated in vitro from CD34(+) hematopoietic progenitors. Cytometry A 2012, 81:294.